// App-Quantinova.ai

: A multi-center, double-blind, randomized, placebo-controlled, Phase IIb dose-finding study to evaluate efficacy and safety of spesolimab in patients with moderate-to-severe palmoplantar pustulosis

Researchers

Presenter

  • A. David Burden

Principal Investigators

  • Robert Bissonnette

  • Alexer A. Navarini

  • Masamoto Murakami

  • Akimichi Morita

  • Susan Mozzicato

  • Binqi Ye

  • Frank Baehner

  • Tadashi Terui

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Department of Gynecological Oncology, University Hospital Basel, Basel, Switzerland

  • Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan

  • Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  • Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

  • Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan

Locations

  • Canada

  • United Kingdom

  • Germany

  • United States

  • China

  • Japan

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Dermatology

Disease

  • Psoriasis 14, pustular

Biomarkers

  • Immunoglobulin G

Drug/Treatment

  • Interleukin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT04015518

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved